BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32260362)

  • 1. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
    Trotta F; Avena P; Chimento A; Rago V; De Luca A; Sculco S; Nocito MC; Malivindi R; Fallo F; Pezzani R; Pilon C; Lasorsa FM; Barile SN; Palmieri L; Lerario AM; Pezzi V; Casaburi I; Sirianni R
    Mol Cancer Ther; 2020 Sep; 19(9):1909-1921. PubMed ID: 32546662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.
    Warde KM; Schoenmakers E; Ribes Martinez E; Lim YJ; Leonard M; Lawless SJ; O'Shea P; Chatterjee KV; Gurnell M; Hantel C; Dennedy MC
    Endocr Relat Cancer; 2020 Jun; 27(6):361-373. PubMed ID: 32276262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
    Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
    Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
    Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
    Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
    Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
    PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.
    Poli G; Guasti D; Rapizzi E; Fucci R; Canu L; Bandini A; Cini N; Bani D; Mannelli M; Luconi M
    Endocr Relat Cancer; 2013 Aug; 20(4):537-50. PubMed ID: 23722227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
    Warde KM; Lim YJ; Ribes Martinez E; Beuschlein F; O'Shea P; Hantel C; Dennedy MC
    Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35797592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
    Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
    Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
    Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
    Corso CR; Acco A; Bach C; Bonatto SJR; de Figueiredo BC; de Souza LM
    Br J Clin Pharmacol; 2021 Jul; 87(7):2698-2710. PubMed ID: 33382119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
    Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
    J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.